David Luo

Dave is Erasca’s Vice President of Clinical Research and Operations, bringing 20 years of early- and late-phase drug development experience across multiple therapeutic areas, with a particular emphasis in oncology. Before Erasca, Dave was vice president of clinical operations at Synthorx, a San Diego biotechnology company acquired by Sanofi, where he was responsible for clinical development and operations of its lead immuno-oncology biologic therapy. Prior to this, he served as vice president of clinical operations at Ignyta, a precision oncology company acquired by Roche, where he led operational oversight of multiple clinical-stage oncology programs, including its lead targeted therapy, Rozlytrek®, which has been approved in the US, Japan and other territories. Prior to Ignyta, Dave held multiple leadership positions within clinical research operations at pharmaceutical and biotechnology companies, including Elevation Pharmaceuticals (acquired by Sunovion Pharmaceuticals) and Meritage Pharma (acquired by Shire). Dave earned a master of public health with an emphasis in toxicology and environmental health sciences from the University of California, Los Angeles and a B.S. in biology from the University of California, San Diego.